Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$4.44 -11.4%	$3.07	$7.96 ▼ $24.15	$22.39M	0.63	15,685 shs	353,215 shs
IMVT Immunovant	$15.40 +1.9%	$16.20	$12.72 ▼ $32.10	$2.68B	0.45	1.49 million shs	1.32 million shs
KRYS Krystal Biotech	$160.61 +4.3%	$147.46	$122.80 ▼ $207.84	$4.65B	0.66	330,474 shs	364,668 shs
RGNX REGENXBIO	$9.36 +3.7%	$8.77	$5.03 ▼ $13.15	$472.81M	1.17	916,757 shs	349,929 shs
SGMO Sangamo Therapeutics	$0.55 +7.3%	$0.53	$0.41 ▼ $3.18	$165.94M	1.2	5.91 million shs	8.68 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	+35.04%	+7.05%	+103.66%	+94.94%	-70.96%
IMVT Immunovant	-1.18%	-6.73%	-0.98%	-4.73%	-48.04%
KRYS Krystal Biotech	-0.21%	+12.07%	+5.30%	+16.63%	-18.60%
RGNX REGENXBIO	-2.48%	-5.64%	+3.67%	+5.37%	-30.27%
SGMO Sangamo Therapeutics	-0.29%	-3.59%	-12.97%	+4.40%	-38.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$4.44 -11.4%	$3.07	$7.96 ▼ $24.15	$22.39M	0.63	15,685 shs	353,215 shs
IMVT Immunovant	$15.40 +1.9%	$16.20	$12.72 ▼ $32.10	$2.68B	0.45	1.49 million shs	1.32 million shs
KRYS Krystal Biotech	$160.61 +4.3%	$147.46	$122.80 ▼ $207.84	$4.65B	0.66	330,474 shs	364,668 shs
RGNX REGENXBIO	$9.36 +3.7%	$8.77	$5.03 ▼ $13.15	$472.81M	1.17	916,757 shs	349,929 shs
SGMO Sangamo Therapeutics	$0.55 +7.3%	$0.53	$0.41 ▼ $3.18	$165.94M	1.2	5.91 million shs	8.68 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	+35.04%	+7.05%	+103.66%	+94.94%	-70.96%
IMVT Immunovant	-1.18%	-6.73%	-0.98%	-4.73%	-48.04%
KRYS Krystal Biotech	-0.21%	+12.07%	+5.30%	+16.63%	-18.60%
RGNX REGENXBIO	-2.48%	-5.64%	+3.67%	+5.37%	-30.27%
SGMO Sangamo Therapeutics	-0.29%	-3.59%	-12.97%	+4.40%	-38.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
IMVT Immunovant	2.83	Moderate Buy	$33.60	118.18% Upside
KRYS Krystal Biotech	2.86	Moderate Buy	$209.00	30.13% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$28.38	203.15% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	718.18% Upside

Current Analyst Ratings Breakdown

Latest IMVT, ALVR, RGNX, KRYS, and SGMO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$240.00
9/8/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$52.00
9/8/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
9/4/2025	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
9/4/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/22/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$219.00 ➝ $216.00
8/22/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$240.00
8/19/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KRYS Krystal Biotech	$290.52M	16.00	$4.82 per share	33.29	$32.90 per share	4.88
RGNX REGENXBIO	$155.78M	3.04	N/A	N/A	$5.24 per share	1.79
SGMO Sangamo Therapeutics	$57.80M	2.87	N/A	N/A	$0.11 per share	5.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	11/10/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.92	32.64	15.93	N/A	40.85%	15.21%	13.81%	11/3/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.44	N/A	N/A	N/A	-112.70%	-66.95%	-34.14%	11/5/2025 (Estimated)
SGMO Sangamo Therapeutics	-$97.94M	-$0.29	N/A	N/A	N/A	-77.48%	-293.05%	-63.85%	11/11/2025 (Estimated)

Latest IMVT, ALVR, RGNX, KRYS, and SGMO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	-$1.38	-$0.25	-$1.38	$40.87 million	$21.36 million
8/7/2025	Q2 2025	SGMO Sangamo Therapeutics	-$0.07	-$0.08	-$0.01	-$0.08	$31.68 million	$18.31 million
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.08	$1.29	+$0.21	$1.29	$95.42 million	$96.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
IMVT Immunovant	N/A	12.32	12.32
KRYS Krystal Biotech	N/A	9.68	9.33
RGNX REGENXBIO	N/A	3.13	3.13
SGMO Sangamo Therapeutics	N/A	1.05	1.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
IMVT Immunovant	47.08%
KRYS Krystal Biotech	86.29%
RGNX REGENXBIO	88.08%
SGMO Sangamo Therapeutics	56.92%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
IMVT Immunovant	1.80%
KRYS Krystal Biotech	13.70%
RGNX REGENXBIO	12.79%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
KRYS Krystal Biotech	210	28.94 million	24.98 million	Optionable
RGNX REGENXBIO	370	50.51 million	44.05 million	Optionable
SGMO Sangamo Therapeutics	480	301.71 million	289.34 million	Optionable

IMVT, ALVR, RGNX, KRYS, and SGMO Headlines

Recent News About These Companies

Jacobs Levy Equity Management Inc. Purchases 555,323 Shares of Sangamo Therapeutics, Inc. $SGMO

September 15 at 3:19 AM | marketbeat.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Average Price Target from Brokerages

September 10, 2025 | americanbankingnews.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Rating of "Moderate Buy" by Analysts

September 8, 2025 | marketbeat.com

Sangamo presents detailed data from STAAR study

September 4, 2025 | msn.com

Sangamo Therapeutics Reveals Promising Phase 1/2 STAAR Study Results for Isaralgagene Civaparvovec as Potential One-Time Treatment for Fabry Disease

September 4, 2025 | quiverquant.comQ

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

September 4, 2025 | globenewswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Down 41.5% in July

August 20, 2025 | marketbeat.com

What Makes Sangamo (SGMO) a New Buy Stock

August 14, 2025 | zacks.com

Analysts Conflicted on These Healthcare Names: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Zimmer Biomet Holdings (ZBH)

August 9, 2025 | theglobeandmail.com

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

July 31, 2025 | globenewswire.com

Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy

July 25, 2025 | msn.com

H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data

July 3, 2025 | msn.com

SGMO - Sangamo Therapeutics Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Morningstar

June 25, 2025 | morningstar.comM

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire

June 25, 2025 | businesswire.com

Sangamo cues up Fabry gene therapy filing on STAAR data

June 25, 2025 | pharmaphorum.comP

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

June 24, 2025 | finanznachrichten.de

Sangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational data

June 24, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT, ALVR, RGNX, KRYS, and SGMO Company Descriptions

AlloVir NASDAQ:ALVR

$4.44 -0.57 (-11.38%)

As of 09/17/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Immunovant NASDAQ:IMVT

$15.40 +0.29 (+1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$15.40 0.00 (0.00%)

As of 06:58 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Krystal Biotech NASDAQ:KRYS

$160.61 +6.56 (+4.26%)

Closing price 04:00 PM Eastern

Extended Trading

$159.35 -1.26 (-0.78%)

As of 05:41 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

REGENXBIO NASDAQ:RGNX

$9.36 +0.33 (+3.65%)

Closing price 04:00 PM Eastern

Extended Trading

$9.36 0.00 (-0.05%)

As of 05:53 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Sangamo Therapeutics NASDAQ:SGMO

$0.55 +0.04 (+7.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.56 +0.01 (+1.64%)

As of 07:10 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMVT, ALVR, RGNX, KRYS, and SGMO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMVT, ALVR, RGNX, KRYS, and SGMO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMVT, ALVR, RGNX, KRYS, and SGMO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT, ALVR, RGNX, KRYS, and SGMO Company Descriptions

AlloVir NASDAQ:ALVR

Immunovant NASDAQ:IMVT

Krystal Biotech NASDAQ:KRYS

REGENXBIO NASDAQ:RGNX

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMVT, ALVR, RGNX, KRYS, and SGMO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMVT, ALVR, RGNX, KRYS, and SGMO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMVT, ALVR, RGNX, KRYS, and SGMO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT, ALVR, RGNX, KRYS, and SGMO Company Descriptions

AlloVir NASDAQ:ALVR

Immunovant NASDAQ:IMVT

Krystal Biotech NASDAQ:KRYS

REGENXBIO NASDAQ:RGNX

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools